Genentech, the manufacturer of Herceptin® (trastuzumab) and Perjeta® (pertuzumab), has established this Pregnancy Registry to learn about pregnancy outcomes and the health of women who have taken Herceptin or Perjeta plus Herceptin within six months prior to conception or during pregnancy. The information gathered in this Registry may supplement other sources of data and assist clinicians and patients in weighing the risks or benefits of being exposed to these medications around conception and during pregnancy. These drugs are not approved for use during pregnancy and women of childbearing potential should be advised to avoid becoming pregnant or nursing while taking Herceptin or Perjeta.
The MotHER Pregnancy Registry is a U.S. - based, prospective, observational study of women with HER2+ breast cancer who were treated with a regimen that contains Herceptin or Perjeta plus Herceptin during pregnancy or within six months prior to conception. Women who are interested in enrolling may contact the Registry directly by calling 1-800-690-6720. This Registry is sponsored by Genentech and is managed by INC Research.
The primary objective of this Pregnancy Registry is to monitor pregnancies exposed to Herceptin or Perjeta plus Herceptin in order to describe adverse pregnancy complications, pregnancy outcomes, fetal/infant outcomes among women with breast cancer treated with Herceptin (either in combination with chemotherapies, or as single agent) and the subset of women treated with Perjeta plus Herceptin during pregnancy or within six months prior to conception. The Registry also monitors if there is a potential increase in the risk of major birth defects."
Due to the observational nature of this Registry, participation in the Registry will not influence or interfere with the treatment plan recommended by the patient's healthcare provider.
If you are interested in additional information, click on contact us for the Registry Coordinating Center.
PERJETA® (pertuzumab) is a HER2/neu receptor antagonist indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
The success of the Registry depends on the continued participation of healthcare providers and pregnant women who have been exposed to Genentech manufactured Herceptin or Perjeta plus Herceptin. Participation from patients and healthcare providers is greatly appreciated.